IRL-2500Potent ETB antagonist CAS# 169545-27-1 |
- Gatifloxacin
Catalog No.:BCC1064
CAS No.:112811-59-3
- Dexrazoxane HCl (ICRF-187, ADR-529)
Catalog No.:BCC1087
CAS No.:149003-01-0
- Doxorubicin (Adriamycin) HCl
Catalog No.:BCC1117
CAS No.:25316-40-9
- Etoposide
Catalog No.:BCC1151
CAS No.:33419-42-0
- Genistein
Catalog No.:BCN5499
CAS No.:446-72-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 169545-27-1 | SDF | Download SDF |
| PubChem ID | 5311192 | Appearance | Powder |
| Formula | C36H35N3O4 | M.Wt | 573.69 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in 1eq. NaOH | ||
| Chemical Name | (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-(4-phenylphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid | ||
| SMILES | CC1=CC(=CC(=C1)C(=O)N(C)C(CC2=CC=C(C=C2)C3=CC=CC=C3)C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)O)C | ||
| Standard InChIKey | UZDORQWMYRRLQV-JHOUSYSJSA-N | ||
| Standard InChI | InChI=1S/C36H35N3O4/c1-23-17-24(2)19-28(18-23)35(41)39(3)33(20-25-13-15-27(16-14-25)26-9-5-4-6-10-26)34(40)38-32(36(42)43)21-29-22-37-31-12-8-7-11-30(29)31/h4-19,22,32-33,37H,20-21H2,1-3H3,(H,38,40)(H,42,43)/t32-,33+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent endothelin receptor antagonist; shows some selectivity for ETB receptors (IC50 values are 1.3 and 94 nM for ETB and ETA receptors respectively). Inhibits ETB receptor-mediated blood pressure increase and renal vascular resistance in rats in vivo. |
IRL-2500 Dilution Calculator
IRL-2500 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7431 mL | 8.7155 mL | 17.431 mL | 34.862 mL | 43.5775 mL |
| 5 mM | 0.3486 mL | 1.7431 mL | 3.4862 mL | 6.9724 mL | 8.7155 mL |
| 10 mM | 0.1743 mL | 0.8716 mL | 1.7431 mL | 3.4862 mL | 4.3578 mL |
| 50 mM | 0.0349 mL | 0.1743 mL | 0.3486 mL | 0.6972 mL | 0.8716 mL |
| 100 mM | 0.0174 mL | 0.0872 mL | 0.1743 mL | 0.3486 mL | 0.4358 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Protostemotinine
Catalog No.:BCN8314
CAS No.:169534-85-4
- RS 17053 hydrochloride
Catalog No.:BCC6874
CAS No.:169505-93-5
- Boc-N-Me-Ala-OH
Catalog No.:BCC3209
CAS No.:16948-16-6
- 3β,7β,15β-trihydroxy-11-oxo-lanosta-8-en-24->20 lactone
Catalog No.:BCC8643
CAS No.:1694587-15-9
- Boc-D-Leu-OH.H2O
Catalog No.:BCC3409
CAS No.:16937-99-8
- Boc-D-Orn(Z)-OH
Catalog No.:BCC3431
CAS No.:16937-92-1
- Nebivolol hydrochloride
Catalog No.:BCC9099
CAS No.:169293-50-9
- Ro 25-6981
Catalog No.:BCC4158
CAS No.:169274-78-6
- Fmoc-Phe(4-F)-OH
Catalog No.:BCC3220
CAS No.:169243-86-1
- Dihydropedicin
Catalog No.:BCN4692
CAS No.:169234-89-3
- Trametol
Catalog No.:BCN6924
CAS No.:169217-47-4
- MTPG
Catalog No.:BCC6820
CAS No.:169209-66-9
- Fmoc-Ala(4-pyridyl)-OH
Catalog No.:BCC3327
CAS No.:169555-95-7
- Otosenine
Catalog No.:BCN2107
CAS No.:16958-29-5
- Florosenine
Catalog No.:BCN2108
CAS No.:16958-30-8
- Floridanine
Catalog No.:BCN2103
CAS No.:16958-31-9
- Floricaline
Catalog No.:BCN2104
CAS No.:16958-32-0
- Deracoxib
Catalog No.:BCC4108
CAS No.:169590-41-4
- Celecoxib
Catalog No.:BCC1099
CAS No.:169590-42-5
- Odoratone
Catalog No.:BCN1105
CAS No.:16962-90-6
- Trichosanatine
Catalog No.:BCN1818
CAS No.:169626-16-8
- Isodonal
Catalog No.:BCN3390
CAS No.:16964-56-0
- Z-Thr(tBu)-OH.DCHA
Catalog No.:BCC2565
CAS No.:16966-07-7
- Ro 60-0175 fumarate
Catalog No.:BCC7196
CAS No.:169675-09-6
Effects of the ETB-selective antagonist IRL 2500 in conscious spontaneously hypertensive and Wistar-Kyoto rats.[Pubmed:8587423]
J Cardiovasc Pharmacol. 1995;26 Suppl 3:S389-92.
The pharmacologic profile of a novel and selective ETB antagonist, IRL 2500 (N-(3,5-dimethylbenzoyl)-N-methyl-(D)-(4-phenylphenyl)-alany l-L-tryptophan) was examined in conscious spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats. The initial vasodepressor response to endothelin-1 (ET-1) and IRL 1620 (0.5 nmol/kg, i.v.) was significantly reduced in conscious WKY rats pretreated with IRL 2500 (10 mg/kg, i.v.). The secondary and sustained pressor response to these agonists, however, was not altered by IRL 2500. The linear peptide antagonist BQ 788, although also inhibiting the initial depressor responses, attenuated the secondary pressor response to IRL 1620 and potentiated the pressor response to ET-1. IRL 2500, administered alone to naive conscious SHRs produced a -37 +/- 8 mm Hg reduction in blood pressure, followed by a secondary pressor response (+38 +/- 7 mm Hg) with a duration exceeding 90 min. Pretreatment with either the ETA-selective antagonist BQ 123 or with the nonselective ETA/ETB antagonist SB 209670 resulted in marked potentiation of the depressor response and significant attenuation of the secondary rise in pressure. These results indicate that in the conscious rat, IRL 2500 acts as an ETB1-selective antagonist. In addition, ETA receptor activation contributes to the sustained pressore response to IRL 2500 in the conscious SHR. Furthermore, IRL 2500 may also exert a non-ET receptor-mediated vasodilation in the SHR.
Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500.[Pubmed:8587424]
J Cardiovasc Pharmacol. 1995;26 Suppl 3:S393-6.
IRL 2500 [N-(3,5-dimethylbenzoyl)-N-methyl-(D)-(4-phenylphenyl)-alany l-L- tryptophan] inhibited the binding of [125I]-endothelin-1 (ET-1) to human ETB (IC50 1.3 +/- 0.2 nM) and ETA (IC50 94 +/- 3 nM) receptors expressed in transfected Chinese hamster ovary (CHO) cells. In in vitro studies, IRL 2500 inhibited the sarafotoxin S6c (STX6c)-mediated contraction of the dog saphenous vein (pKb 7.77) and the STX6c-induced relaxation of the preconstricted rabbit mesenteric artery (pKb 6.92). In the anesthetized rat, IRL 2500 (10 mg/kg, i.v.) inhibited the initial transient decrease in mean arterial pressure (MAP) induced by the ETB-selective agonist IRL 1620 (0.5 nmol/kg, i.v.). IRL 2500 also attenuated the IRL 1620-mediated increase in renal vascular resistance (RVR) in the anesthetized rat. Therefore, IRL 2500 is a potent and selective ETB receptor antagonist that can be used to delineate ET responses mediated by the ETB receptor.
Use of A-192621 and IRL-2500 to unmask the mesenteric and renal vasodilator role of endothelin ET(B) receptors.[Pubmed:11904527]
J Cardiovasc Pharmacol. 2002 Apr;39(4):533-43.
Endothelin-1 (ET-1) is known to cause a transient (<1 min) depressor followed by a sustained (>1 h) pressor response. The former through the activation of ET(B) receptors, and the latter through the activation of ET(A) and ET(B) receptors. This study examines if ET(B) receptors mediate sustained mesenteric and renal dilation in anesthetized rats. Intravenous bolus ET-1 (0.8, 1.4, and 2 nmol/kg) and IRL-1620 (ET(B) agonist, 2, 5, and 10 nmol/kg) caused transient decrease followed by sustained increases in mean arterial pressure (MAP) that were accompanied by increases in total peripheral resistance (TPR), reductions in cardiac output (CO), and mesenteric and renal vasoconstriction. Pretreatment with FR-139317 (ET(A) antagonist, 1 mg/kg) attenuated the pressor and constrictor effects of ET-1 but did not alter responses to IRL-1620. IRL-2500 (ET(B) antagonist, 5 mg/kg) slightly inhibited the renal constrictor effect of IRL-1620, whereas A-192621 (ET(B) antagonist, 5 mg/kg) abolished all hemodynamic responses to IRL-1620. Both IRL-2500 and A-192621 markedly enhanced MAP, TPR, and mesenteric, and the renal constrictor effects of ET-1. Therefore, A-192621 was more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmented constrictor responses to ET-1. The potentiation of ET-1-induced vasoconstriction by ET(B) receptor antagonists revealed a sustained vasodilator role of ET(B) receptors.
